For the quarter ending 2025-09-30, AVDL made $77,467K in revenue. $20K in net income. Net profit margin of 0.03%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net product revenue | 77,467 | 68,129 | 52,511 | 38,794 |
| Cost of products sold | -4,116 | 6,366 | 5,577 | 3,167 |
| Gross profit | 81,583 | 61,763 | 46,934 | 35,627 |
| Research and development expenses | 27,010 | 4,255 | 4,354 | 3,671 |
| Selling, general and administrative expenses | 52,636 | 48,624 | 45,581 | 46,622 |
| Total operating expense | 79,646 | 52,879 | 49,935 | 50,293 |
| Operating income (loss) | 1,937 | 8,884 | -3,001 | -14,665 |
| Investment and other income, net | 532 | -34 | 397 | 1,207 |
| Interest expense | 2,415 | 2,355 | 2,238 | 2,647 |
| Income (loss) before income taxes | 54 | 6,495 | -4,842 | -16,105 |
| Income tax provision (benefit) | 34 | -3,170 | 78 | 87 |
| Net income (loss) | 20 | 9,665 | -4,920 | -16,192 |
| Net income (loss) per share - basic (in dollars per share) | 0 | 0.1 | -0.05 | -0.17 |
| Net income (loss) per share - diluted (in dollars per share) | 0 | 0.1 | -0.05 | -0.17 |
| Weighted average number of shares outstanding - basic (in shares) | 97,104,000 | 96,726,000 | 96,601,000 | -48,655,000 |
| Weighted average number of shares outstanding - diluted (in shares) | 101,276,000 | 99,087,000 | 96,601,000 | -48,655,000 |
AVADEL PHARMACEUTICALS PLC (AVDL)
AVADEL PHARMACEUTICALS PLC (AVDL)